120 related articles for article (PubMed ID: 17564707)
1. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Cashen AF; Shah AK; Todt L; Fisher N; DiPersio J
Cancer Chemother Pharmacol; 2008 Apr; 61(5):759-66. PubMed ID: 17564707
[TBL] [Abstract][Full Text] [Related]
2. Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review.
Haumschild R; Kennerly-Shah J; Barbarotta L; Zeidan AM
J Oncol Pharm Pract; 2024 Jun; 30(4):721-736. PubMed ID: 38509812
[TBL] [Abstract][Full Text] [Related]
3. Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen.
Ali AM; Weisel D; Gao F; Uy GL; Cashen AF; Jacoby MA; Wartman LD; Ghobadi A; Pusic I; Romee R; Fehniger TA; Stockerl-Goldstein KE; Vij R; Oh ST; Abboud CN; Schroeder MA; Westervelt P; DiPersio JF; Welch JS
Cancer Med; 2017 Dec; 6(12):2814-2821. PubMed ID: 29058375
[TBL] [Abstract][Full Text] [Related]
4. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial.
Steensma DP; Baer MR; Slack JL; Buckstein R; Godley LA; Garcia-Manero G; Albitar M; Larsen JS; Arora S; Cullen MT; Kantarjian H
J Clin Oncol; 2009 Aug; 27(23):3842-8. PubMed ID: 19528372
[TBL] [Abstract][Full Text] [Related]
5. Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes.
Garcia-Manero G; Jabbour E; Borthakur G; Faderl S; Estrov Z; Yang H; Maddipoti S; Godley LA; Gabrail N; Berdeja JG; Nadeem A; Kassalow L; Kantarjian H
J Clin Oncol; 2013 Jul; 31(20):2548-53. PubMed ID: 23733767
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine.
Jabbour E; Garcia-Manero G; Ravandi F; Faderl S; O'Brien S; Fullmer A; Cortes JE; Wierda W; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):131-8. PubMed ID: 23260600
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine.
Jabbour E; Kantarjian H; O'Brien S; Kadia T; Malik A; Welch MA; Teng A; Cortes J; Ravandi F; Garcia-Manero G
Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):592-6. PubMed ID: 23790798
[TBL] [Abstract][Full Text] [Related]
8. Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome.
Ghanem H; Cornelison AM; Garcia-Manero G; Kantarjian H; Ravandi F; Kadia T; Cortes J; O'Brien S; Brandt M; Borthakur G; Jabbour E
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2(0 2):S289-94. PubMed ID: 23969308
[TBL] [Abstract][Full Text] [Related]
9. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies.
Jabbour E; Issa JP; Garcia-Manero G; Kantarjian H
Cancer; 2008 Jun; 112(11):2341-51. PubMed ID: 18398832
[TBL] [Abstract][Full Text] [Related]
10. The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes.
Jabbour E; Garcia-Manero G; Cornelison AM; Cortes JE; Ravandi F; Daver N; Kadia T; Teng A; Kantarjian H
Leuk Lymphoma; 2015 Feb; 56(2):390-4. PubMed ID: 24844364
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics of Oral Azacitidine, and Exposure-Response Analysis in Acute Myeloid Leukemia.
Gaudy A; Laille E; Bailey R; Zhou S; Skikne B; Beach CL
Clin Pharmacol Ther; 2023 Oct; 114(4):845-852. PubMed ID: 37422689
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of therapy with hypomethylating agents in patients with renal insufficiency.
Batty GN; Kantarjian H; Issa JP; Jabbour E; Santos FP; McCue D; Garcia-Manero G; Pierce S; O'Brien S; Cortés JE; Ravandi F
Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):205-10. PubMed ID: 20511166
[TBL] [Abstract][Full Text] [Related]
13. A comparison of toxicities in acute myeloid leukemia patients with and without renal impairment treated with decitabine.
Levine LB; Roddy JV; Kim M; Li J; Phillips G; Walker AR
J Oncol Pharm Pract; 2018 Jun; 24(4):290-298. PubMed ID: 28345491
[TBL] [Abstract][Full Text] [Related]
14. Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings.
Garcia JS; Flamand Y; Penter L; Keng M; Tomlinson BK; Mendez LM; Koller P; Cullen N; Arihara Y; Pfaff K; Wolff JO; Brunner AM; Galinsky I; Bashey A; Antin JH; Cutler C; Ho V; Jonas BA; Luskin MR; Wadleigh M; Winer ES; Savell A; Leonard R; Robertson T; Davids MS; Streicher H; Rodig SJ; Ritz J; Wu CJ; DeAngelo DJ; Neuberg D; Stone RM; Soiffer RJ
Blood; 2023 Apr; 141(15):1884-1888. PubMed ID: 36332187
[TBL] [Abstract][Full Text] [Related]
15. Recurrent transcriptional responses in AML and MDS patients treated with decitabine.
Upadhyay P; Beales J; Shah NM; Gruszczynska A; Miller CA; Petti AA; Ramakrishnan SM; Link DC; Ley TJ; Welch JS
Exp Hematol; 2022 Jul; 111():50-65. PubMed ID: 35429619
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML).
Ravandi F; Gojo I; Patnaik MM; Minden MD; Kantarjian H; Johnson-Levonas AO; Fancourt C; Lam R; Jones MB; Knox CD; Rose S; Patel PS; Tibes R
Leuk Res; 2016 Sep; 48():92-100. PubMed ID: 27544076
[TBL] [Abstract][Full Text] [Related]
17. Reciprocal regulation of TWIST1 and OGT determines the decitabine efficacy in MDS/AML.
Li H; Wang Y; Feng S; Chang K; Yu X; Yang F; Huang H; Wang Y; Li X; Guan F
Cell Commun Signal; 2023 Sep; 21(1):255. PubMed ID: 37736724
[TBL] [Abstract][Full Text] [Related]
18. Mass balance and metabolite profiling of
Roosendaal J; Rosing H; Lucas L; Gebretensae A; Huitema ADR; van Dongen MG; Beijnen JH; Oganesian A
Invest New Drugs; 2020 Aug; 38(4):1085-1095. PubMed ID: 31605293
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of a continuous intravenous infusion of hydromorphone in healthy dogs.
Wimbish C; Lynch AM; Knych HK; Ueda Y; Messenger KM
Front Vet Sci; 2024; 11():1362730. PubMed ID: 38686029
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and Biodistribution of 16,16 dimethyl Prostaglandin E2 in Non-Irradiated and Irradiated Mice and Non-Irradiated Non-Human Primates.
Langevin B; Singh P; Plett PA; Sampson CH; Masters A; Gibbs A; Faria E; Triesler S; Zodda A; Jackson IL; Orschell CM; Gopalakrishnan M; Pelus LM
Radiat Res; 2024 Jan; 201(1):7-18. PubMed ID: 38019093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
